Jiangsu Hengrui Pharmaceuticals (01276) released its first quarter results, with a net profit attributable to shareholders of 2.282 billion yuan, an increase of 21.78% year-on-year.

Jiangsu Hengrui Pharmaceuticals (01276) announced that in the first quarter of 2026, the group achieved operating income of 8.141 billion yuan (same unit), an increase of 12.98% year-on-year; net profit attributable to shareholders of the listed company was 2.282 billion yuan, an increase of 21.78% year-on-year; basic earnings per share were 0.34 yuan. In the first quarter of 2026, the company's sales revenue from innovative drugs was 4.526 billion yuan, a year-on-year increase of 25.75%, accounting for 61.69% of drug sales revenue. Among the sales revenue from innovative drugs, revenue from anticancer products was 3.313 billion yuan, a year-on-year increase of 11.63%, accounting for 73.20% of the total sales revenue from innovative drugs. Revenue from non-cancer products was 1.213 billion yuan, a year-on-year increase of 92.13%, accounting for 26.80% of the total sales revenue from innovative drugs. With the continuous approval of new products and new indications, as well as the gradual inclusion of innovative drugs covered by medical insurance, the company aims to achieve a growth of over 30% in sales revenue from innovative drugs for the whole year. The company reported revenue of 0.787 billion yuan from the licensing of innovative drugs to external parties during the reporting period, mainly due to income recognized by GSK based on the progress of fulfilling obligations. Affected by factors such as national and local group procurement and the contraction of strategic resource input, sales revenue from generic drugs decreased during the reporting period. With the continued growth of sales revenue from innovative drugs, the proportion of sales revenue from generic drugs in the total sales revenue will gradually decrease, further optimizing the company's revenue structure, and making the development pattern driven by innovation more stable.